[혁신형 제약기업 점검]⑤ 일동제약, 인증 방패 쥐고 R&D 내재화

Illdong Pharmaceutical leverages its innovative pharmaceutical certification status to gain defensive advantages against upcoming drug pricing reforms, while consolidating R&D capabilities through subsidiary merger. However, the company's actual value and strategic success fundamentally depend on advancing its GLP-1RA oral obesity treatment candidate and P-CAB GERD treatment through global partnerships and clinical progression, as regulatory protection alone cannot fill revenue gaps from recent restructuring.